Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults

NCT07209683 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this pilot clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in older adults. The main questions it aims to answer are: * Does tPBM enhance neurovascular coupling responses during memory and finger tapping tasks? * Are these improvements linked to better cognitive performance and lower levels of brain inflammation and oxidative stress? Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation. Participants will: * Receive either active tPBM or sham stimulation sessions for 4 weeks, every other day using a portable intervention device. * Complete questionnaires and an iPAD-based cognitive testing protocol * Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG), transcranial doppler (TCD) flowmetry. * Retinal vessel reactivity will be measured during flickering light stimulus using a special camera (dynamic vessel analysis, DVA). * Provide blood samples to test for biomarkers of inflammation, oxidative stress and brain cell damage.

Interventions

  • DEVICE transcranial photobiomodulation

Study Locations (1)

Oklahoma

  • University of Oklahoma Health Campus — Oklahoma City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-10-01
Est. Completion 2026-12-31
Phase NA

Sponsor

University of Oklahoma

306 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07209683

The ClinicalTrials.gov registry entry for NCT07209683 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 306 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Cognition appearing as the primary indexed condition, and to 1 intervention — of which transcranial photobiomodulation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07209683 reports 1 study location spanning 1 distinct geographic area — top geographies include Oklahoma. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07209683 about?

NCT07209683 is a clinical study titled "The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults". The goal of this pilot clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in older adults. The main questions it aims ...

What is the current status of trial NCT07209683?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-10-01. Estimated completion is 2026-12-31.

What conditions does trial NCT07209683 study?

This clinical trial studies the following conditions: Cognition, Brain Aging, Neurovascular Control, Neurovascular Coupling Mechanism and Cognitive Function, Brain Activity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07209683?

The interventions under investigation include: transcranial photobiomodulation (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07209683?

This trial is sponsored by University of Oklahoma, which has 306 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07209683 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial